Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|25|31|3682-3702

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.25, Iss.31, 2018-09, pp. : 3682-3702

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CCR1 Antagonists: What Have We Learned From Clinical Trials

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 13, 2010-09 ,pp. : 1268-1277

Bentham Science Publishers

Access to resources Recommend Favorite

On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?

By  

Current Medicinal Chemistry, Vol. 15, Iss. 23, 2008-10 ,pp. : 2305-2320

Bentham Science Publishers

Access to resources Recommend Favorite

Prospects for the treatment of Parkinson’s disease using neurotrophic factors

By Hurelbrink Carrie B   Barker Roger A  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 10, 2001-10 ,pp. : 1531-1543

Informa Healthcare

Access to resources Recommend Favorite

Implementing NICE clinical guidelines on Parkinson’s disease

By Ryton Beverly A   Liddle B Jane  

Clinical Medicine, Vol. 9, Iss. 5, 2009-10 ,pp. : 436-440

Royal College Of Physicians

Access to resources Recommend Favorite

Personalizing HER2-Targeted Therapy in Metastatic Breast Cancer Beyond HER2 Status: What We Have Learned from Clinical Specimens

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 4, 2009-12 ,pp. : 263-274

Bentham Science Publishers

Access to resources Recommend Favorite